What Are CDK4/6 Inhibitors? CDK4/6 inhibitors, such as abemaciclib and ribociclib, are changing breast cancer treatment for HR+/HER2- early-stage patients. Specifically, these drugs target a key cell growth pathway to tackle hormone therapy resistance, a major issue in high-risk cases. For example, Dr. Austin Williams, a breast surgeon at Fox Chase Cancer Center, explains in … Continue reading Breast Cancer Treatment: How CDK4/6 Inhibitors Work (monarchE & NATALEE Trials)